Karen H. Vousden
Scientific Co-Founder & DirectorDr. Karen H. Vousden, Ph.D, is Member of Scientific Advisory Board of Kovina Therapeutics Inc. She is Scientific Co-Founder at Sensei Biotherapeutics, Inc. since 2026. She is scientific co-founder of Faeth Therapeutics, Inc. and serves as Director since September 11, 2026. She is the Director of Bristol-Myers Squibb Company from January 01, 2018. She is the Founder and Consultant of Faeth Therapeutics, Inc. She served as the Chief of the Regulation at Cell Growth Laboratory at the NCI before 2002. Dr. Vousden had been a Director of American Association for Cancer Research since April 2, 2012. She has been Senior Group leader at the Francis Crick Institute in London since February 2017. She served as the Chief Scientist at Cancer Research UK since July 2016 until, 2022, where she is responsible for focusing on the role of basic science in the treatment of cancer. She served as a Member of Scientific Advisory Board at PMV Pharmaceutcals, Inc. until 2024. She serves as Member of International Scientific Advisory Board at Istituto Europeo di Oncologia s.r.l. She is Scientific Editor for Cancer Discovery. She serves on the Board of Directors of the AACR. Dr. Vousden serves as Member of Scientific Advisory Board of Raze Therapeutics, Inc. Dr. Vousden was Director of the Beatson Institute for Cancer Research in Glasgow, Scotland from 2002 to 2016. She held leadership roles at the National Cancer Institute in Maryland (1995-2002). She is a Member of Molecular Cancer Research Editorial Board. She is a Co-Chairperson of the Annual Meeting Program Committee and a Steering Committee Member of the Council of Scientific Advisors. Dr. Vousden was elected to the Royal Society, the Royal Society of Edinburgh, EMBO and the Academy of Medical Sciences and the European Academy of Sciences. She is a Member of the Science Advisory Board of Kovina Therapeutics, the University Cancer Center Frankfurt, Ludwig Institute for Cancer Research, PMV Pharma, Raze Therapeutics and Volastra Therapeutics. She is a Council member of the European Molecular Biology Organization and President of the British Association of Cancer Research. She is Professor of Cancer Biology at The Beatson Institute for Cancer Research. Dr. Vousden is a world authority on p53 and tumor suppression. She was awarded the Sir Frederick Gowland Hopkins Medal in 2008, the Royal Medal from the Royal Society of Edinburgh in 2009 and was honored as Commander of the British Empire in 2010. Dr. Vousden received her Ph.D. in Genetics from Queen Mary College at the University of London, followed by Postdoctoral Fellowships with Chris Marshall at the Institute of Cancer Research in London and Douglas Lowy at the National Cancer Institute in the USA.
Positions
- Company NameFaeth Therapeutics, Inc.Stock CodeFTHPositionScientific Co-Founder & DirectorColleagues
- JCJosiah CraverSenior VP of Finance, Principal Financial Officer & Principal Accounting Officer
- APAnand ParikhCEO, President & Chair
- CWChristopher W. GerryGeneral Counsel & Secretary
- SMSiddhartha MukherjeeScientific Co-Founder
- LCLewis clayton CantleyScientific Co-Founder
- KHKaren H. VousdenScientific Co-Founder & Director
- RHRobert HolmenIndependent Director
- PBPhillip B. DonenbergIndependent Director
- SSSona Saira Gonsalves RamasastryDirector
- Company NameBristol-Myers Squibb CompanyStock CodeBMYPositionIndependent DirectorRelated SecuritiesColleagues
- CSChristopher S. BoernerCEO & Chairman
- DVDavid V. ElkinsExecutive VP & CFO
- GMGreg MeyersExecutive VP and Chief Digital & Technology Officer
- ALAdam LenkowskyExecutive VP & Chief Commercialization Officer
- CMCristian MassacesiExecutive VP, Chief Medical Officer & Head of Development
- PJPeter J. ArduiniIndependent Director
- TRTheodore Rapp SamuelsLead Independent Director
- DWDerica W. RiceIndependent Director
